Matches in UGent Biblio for { <https://biblio.ugent.be/publication/694211#aggregation> ?p ?o. }
Showing items 1 to 32 of
32
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B571334.
- aggregation creator B571335.
- aggregation creator B571336.
- aggregation creator B571337.
- aggregation creator person.
- aggregation creator person.
- aggregation date "2007".
- aggregation hasFormat 694211.bibtex.
- aggregation hasFormat 694211.csv.
- aggregation hasFormat 694211.dc.
- aggregation hasFormat 694211.didl.
- aggregation hasFormat 694211.doc.
- aggregation hasFormat 694211.json.
- aggregation hasFormat 694211.mets.
- aggregation hasFormat 694211.mods.
- aggregation hasFormat 694211.rdf.
- aggregation hasFormat 694211.ris.
- aggregation hasFormat 694211.txt.
- aggregation hasFormat 694211.xls.
- aggregation hasFormat 694211.yaml.
- aggregation isPartOf urn:issn:1824-4661.
- aggregation language "eng".
- aggregation title "Iodine-123-interleukin-2 scintigraphy in metastatic hypernephroma: a pilot study".
- aggregation abstract "Aim This pilot study reports on the uptake of I-123-interleukin 2 (IL-2) in metastatic renal cell carcinoma (MRCC) patients and its relationship to prognostic factors of response or failure of MRCC to cytokines treatment. Methods. Nine consecutive patients with MRCC underwent an I-123-IL-2 scan (6 male and 3 female; mean age 64 years; range 51-78). Uptake in metastases was related to a summed score of 4 independent factors, predictive of rapid progression under cytokine treatment as defined by Negrier et al. Results. Four patients presented with metastases at one site, 4 at 2 sites and one patient at 3 different sites. Summed scores were: 5 patients had a summed score of 1; 3 a summed score of 2 and I patient a summed score of 3. Uptake of I-123-IL-2 by tumor tissue was found in only 2 patients. Uptake occurred in I patient with a summed score of 3 and in 1 with a summed score of 2. Conclusion In this small series of patients with MRCC, I-123-IL-2 uptake was found in tumors of 2 patients who less likely will benefit from cytokine treatment. Additional studies are needed to assess the relationship between the pretreatment uptake of I-123-IL2 in MRCC and the response to IL-2 therapy.".
- aggregation authorList BK921763.
- aggregation endPage "356".
- aggregation issue "4".
- aggregation startPage "352".
- aggregation volume "51".
- aggregation isDescribedBy 694211.
- aggregation similarTo LU-694211.